52w high/low | ₹404.8 / ₹280.5 |
P/E ratio | 37.79 |
Dividend | 0.26 |
ROE | 11.68 |
ROCE | 14.74 |
Face value | 1 |
Book value | ₹132.5Cr |
Market capital | ₹14,178.57Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Granules India Limited is a large-scale vertically integrated company founded in March 18th, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin. The company has a global presence across over 60 countries servicing over 250 customers. Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. The company has one of largest PFI and single site FD facilities in the world. It is also home to one of the World's largest Paracetamol API facilities. Granules India has eight manufacturing facilities, out of which six are located in India and one in the US. It also has two operational manufacturing units located in India and China through its joint venture entities.